Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 60, Issue 4, 1996, Pages 452-454

  Rösler, Norbert ^a,b   Wichart, Ildiko ^a   Jellinger, Kurt A ^a  

^a GENERAL HOSPITAL LINZ   (Austria)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cerebrospinal fluid

Indexed keywords

APOLIPOPROTEIN E; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIPOPROTEIN BLOOD LEVEL; MALE; NEUROCHEMISTRY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SCORING SYSTEM;

EID: 0030000392     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.60.4.452     Document Type: Article

References (17)

1. Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 1990;95:239-58.
2. Galasko D, Hansen LA, Katzman R, et a/. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888-95.
3. Hock C, Golombowski S, Naser W, Müller-Spahn F. Increased levels of tau-protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann Neurol 1995;37: 414-5.
4. Van de Voorde A, Vanmechelen E, Vandermeeren M, Dessaint F, Beckman W, Gras P. Detection of tau in cerebrospinal fluid. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, eds. Research advances in Alzheimer's disease and related disorders. John Wiley, 1995:189-95.
5. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994;17: 525-30.
6. Namba Y, Tomanaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991;541:163-6.
7. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble Alzheimer's β-amyloid. Biochem Biophys Res Comm 1993; 192:359-65.
8. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-8.
9. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late onset familial Alzheimer's disease. Proc Nad Acad Sci USA 1993;90: 1977-81.
10. Martinoli MG, Trojanowski JQ, Schmidt ML, et al. Association of apolipoprotein ε4 allele and neuropathologic findings in patients with dementia. Acta Neuropathol 1996 (in press).
11. Folstein MF, Folstein SE, McHugh PR. "Mini mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
12. Khachaturian Z. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-105.
13. Tiemey MC, Fisher RW, Lewis AJ, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease. A clinicopathologic study of 57 cases. Neurology 1988;38:359-64.
14. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:306-15.
15. Carlsson J, Armstrong VW, Reiber H, Felgenhauer K, Seidel D. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chim Acta 1991;196:167-76.
16. Blennow K, Hesse C, Fredman P. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport 1994;5:2534-6.
17. Rösler N, Wichart I, Jellinger KA. Total tau protein immunoreactivity in lumber cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996;60:237.